The successful mRNA melanoma skin cancer vaccine brought in partner Merck & Co., $MRK.US , up 5%
Post
--Bullish
价值与动量发掘
·
--
BullishModerna (MRNA) surged 30% premarket. The company announced with Merck & Co. that its melanoma skin cancer vaccine met its goals in a large trial, in an impact trial. $MRNA.US
Disclaimer: Includes third-party opinions. No advice. Binance AI may be used without guarantee. See T&Cs.
MRKUS+0.47%